Pharmaceuticals & Therapeutics

The eye health giant has refinanced a massive $2.8B in loans, extending debt maturity and cutting interest costs to bolster its long-term strategy.

All eyes are on GH Research ahead of a crucial Jan. 5 announcement on the FDA status of its fast-acting drug for treatment-resistant depression.

A major new partnership is funding research to develop vital diagnostic tests for FTD, aiming to end years-long diagnostic delays for families.

Lantheus sells its legacy SPECT business to fusion-tech firm SHINE, sharpening its focus on high-growth PET diagnostics and next-gen cancer therapies.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

Samsung Bioepis is now directly selling its Lucentis biosimilar in Europe, a move set to increase competition and improve access to vital eye disease treatments.

Neovii Pharmaceuticals names Frédéric Prince its next CEO, bringing deep oncology and gene therapy experience from Roche to steer its next growth phase.

South Korea's KLMBio is accelerating its global push with major investments in production and new products to capture the booming regenerative medicine market.

World No.1 table tennis star Sun Yingsha joins La Roche-Posay in a strategic play for Gen-Z hearts and the massive Asian beauty market.

AI drug discovery firm Insilico Medicine soars in its Hong Kong debut, the city's largest biotech IPO of 2025, validating a new tech-driven era for medicine.

With strong financials and new clinical data, medical device leader Penumbra is set to detail its growth strategy at healthcare's top investor event.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

KORU Medical seeks FDA clearance for its FreedomEDGE® system with a key breast cancer drug, signaling a major shift in cancer care delivery.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

With soaring revenue and a landmark FDA approval for its Shield cancer test, Guardant Health's upcoming JPM presentation is poised to define its future.

A new $1,000 grant aims to foster compassion in future doctors, but its founder, a prominent psychiatrist, recently pleaded guilty to healthcare fraud.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

StimLabs secures FDA clearance for Theracor, the first-ever umbilical cord sheet device, offering new hope for patients with hard-to-heal chronic wounds.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.